JAK1
Tyrosine-protein kinase JAK1
As of the edition of 20 October 2026, JAK1 (tyrosine-protein kinase JAK1, UniProt P23458) has 27 drugs tested at it and 27 companies on the list, 4 on route A and 8 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23458
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 52
- Disease areas
- Skin and connective tissue; Immune system; Blood and lymph; Cancer; Bones, joints and muscles; Lungs and airways; Inherited and neonatal; Digestive system
- Registered trials of its drugs
- 1,297
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 10 |
| Active | 6 |
| Went quiet | 3 |
| Stopped | 6 |
| Status not established | 2 |
| Total | 27 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ruxolitinib | Marketed | Phase 4 | Ends 2029 |
| Tofacitinib | Marketed | Phase 4 | Ends 2028 |
| Baricitinib | Marketed | Phase 4 | Ends 2032 |
| Upadacitinib | Marketed | Phase 4 | Ends 2036 |
| Filgotinib | Marketed | Phase 4 | none listed |
| Itacitinib | Active | Phase 3 | none listed |
| Abrocitinib | Marketed | Phase 4 | Ends 2036 |
| Golidocitinib | Active | Phase 3 | none listed |
| Ivarmacitinib | Stopped | Phase 4 | none listed |
| Peficitinib | Marketed | Phase 3 | none listed |
| Brepocitinib | Marketed | Phase 3 | none listed |
| Momelotinib | Marketed | Phase 3 | Ends 2035 |
12 of 27 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 8 |
| Engaged | 10 |
| Undetermined | 5 |
| Total on the list | 27 |
The other 24 companies at JAK1
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at JAK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.